Market Research Logo

Infantile Spasm Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Infantile Spasm Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Report Description

Infantile spasm is a rare disorder that appears as seizures in infants below 1 year. Infantile spasm causes series of sudden, jerking movements of legs and arms or fast drop of head. The duration of spasm can last up to couple of seconds. Major drugs used for the treatment of infantile spasm include adrenocorticotropic hormone (ACTH), however, due to its side effects, doctors also prefer anti-seizure drugs such as vigabatrin and other steroid therapies.

Market Dynamics

Increasing prevalence of central nervous system infection, may develop infantile spasm which in turn is expected to boost the infantile spasm treatment market. According to the National Center for Biotechnology Information (NCBI), in January 2018, the prevalence of infantile spasm was 2 to 3.5 infants per 10,000 live births.

Government initiatives for rare disease treatment is expected to boost the market growth. For instance, The American Academy of Pediatrics also works with the Child Neurology Society, Child Neurology Foundation, American College of Emergency Physicians, and other partners to build advocacy, identify awareness gaps, and expand outreach opportunities.

The relapse or reoccurrence of infantile spasm is a major factor driving growth of the infantile spasm treatment market. According to investigators from Okayama University Hospital, Japan, after the treatment of infantile spasm with ACTH therapy for 11 to 37 days, the disease reoccurred in 41% of the people under study.

Moreover, the government of Brazil in year 2017 amended its regulatory rules for approving drugs for rare disease. In December 2017, Brazilian regulatory agency, Agência Nacional de Vigilância Sanitária (ANVISA) published Resolution RDC 205/2017, regulating special procedures for clinical trials, registration, and certification of Good Manufacturing Practices (GMPs) of drugs intended to treat, prevent or diagnose rare diseases such as infantile spasm.

Key features of the study:

  • This report provides in-depth analysis of the infantile spasm treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global infantile spasm treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals plc, Retrophin, Inc., Valerion Therapeutics, Orphelia Pharma SA, Insys Therapeutics, Inc., and Anavex Life Sciences Corp.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global infantile spasm treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the infantile spasm treatment market
Detailed Segmentation:
  • Global Infantile Spasm Treatment Market, By Product Type:
  • Adrenocorticotropic Hormone (ACTH)
  • Vigabatrin
  • Phase III
  • Global Infantile Spasm Treatment Market, By Route of Administration:
  • Oral
  • Parenteral
  • Global Infantile Spasm Treatment Market, By Region:
  • North America
  • By Product Type:
  • Adrenocorticotropic Hormone (ACTH)
  • Vigabatrin
  • Phase III
  • By Route of Administration:
  • Oral
  • Parenteral
  • By Country:
  • U.S.
  • Canada
  • Latin America
  • By Product Type:
  • Adrenocorticotropic Hormone (ACTH)
  • Vigabatrin
  • Phase III
  • By Route of Administration:
  • Oral
  • Parenteral
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Product Type:
  • Adrenocorticotropic Hormone (ACTH)
  • Vigabatrin
  • Phase III
  • By Route of Administration:
  • Oral
  • Parenteral
  • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Product Type:
  • Adrenocorticotropic Hormone (ACTH)
  • Vigabatrin
  • Phase III
  • By Route of Administration:
  • Oral
  • Parenteral
  • By Country:
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • By Product Type:
  • Adrenocorticotropic Hormone (ACTH)
  • Vigabatrin
  • Phase III
  • By Route of Administration:
  • Oral
  • Parenteral
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Product Type:
  • Adrenocorticotropic Hormone (ACTH)
  • Vigabatrin
  • Phase III
  • By Route of Administration:
  • Oral
  • Parenteral
  • By Country:
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • H. Lundbeck A/S*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Highlights
  • Market Strategies
  • Mallinckrodt Pharmaceuticals
  • Catalyst Pharmaceuticals
  • GW Pharmaceuticals plc
  • Retrophin, Inc.
  • Valerion Therapeutics
  • Orphelia Pharma SA
  • Insys Therapeutics, Inc.
  • Anavex Life Sciences Corp.
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Product Type
Market Snippet, By Route Of Administration
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Diagnostic Algorithm For Infantile Spasms
Treatment Options In Infantile Spasms
Relapse In Infantile Spasms
Pipeline Analysis
Organizations Providing Infantile Spasms Information
Challenges Faced By Rare Disease Drug Discovery Programs
Reimbursement Scenario
Epidemiology
Pest Analysis
4. Global Infantile Spasm Treatment Market, By Product Type, 2018 – 2026, (US$ Mn)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Adrenocorticotropic Hormone (ACTH)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Vigabatrin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Phase III
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
5. Global Infantile Spasm Treatment Market, By Route of Administration, 2018 – 2026, (US$ Mn)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Parenteral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
6. Global Infantile Spasm Treatment Market, By Region, 201 – 2026, (US$ Mn)
Introduction
Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, For Regions, 2017–2026
North America
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
U.S.
Canada
Latin America
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of APAC
Middle East
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
South Africa
Central Africa
North Africa
7. Competitive Landscape
Heat Map Analysis
Company Profiles
H. Lundbeck A/S
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
Mallinckrodt Pharmaceuticals
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
Catalyst Pharmaceuticals
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
GW Pharmaceuticals plc
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
Retrophin, Inc.
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
Valerion Therapeutics
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
Orphelia Pharma SA
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
Insys Therapeutics, Inc.
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
Anavex Life Sciences Corp.
Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies
Analyst Views
8. Section
References
Research Methodology
About us and Sales Contact
*Browse 39 market data tables and 29 figures on "Infantile Spasm Treatment Market - Global forecast to 2026”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report